Related Experiment Video
Updated: May 3, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Cost-effective optimisation and validation of the VISAGE enhanced tool assay on the Illumina NovaSeq 6000 platform
Lauren Verstraeten1, Kristina Fokias1, Gitte Saerens1
1UZ Leuven, Laboratory of Forensic Genetics, Leuven, Belgium; KU Leuven, Forensic Biomedical Sciences, Department of Imaging & Pathology, Leuven, Belgium.
Abstract:
Numerous forensic age prediction models based on DNA methylation markers have been developed, each differing in the number of predictive markers, statistical method, biomatrix, and sequencing platform used. This variability highlighted the need for more uniformity in the development of epigenetic clocks. To partially address this need, the VISAGE Consortium introduced the VISAGE enhanced tool assay, a multi-tissue assay that targets eight age-associated genes (ELOVL2, EDARADD, ASPA, FHL2, MIR29B2CHG, KLF14, TRIM59, and PDE4C). So far, three models were built using this assay for age prediction in blood, buccal cells, and bones, based on Illumina MiSeq sequencing data with the v3 reagent kit (2 × 300 bp). Unfortunately, the existing models are neither publicly accessible nor permitted for use in forensic casework. To address this limitation, we developed our own age estimation model utilising the VISAGE enhanced tool assay in combination with the Illumina NovaSeq 6000 platform and the v1.5 reagent kit (2 × 150 bp). By employing the same assay, we streamlined the workflow and enhanced uniformity, as there was no need to identify additional age-associated genes. By adjusting the assay's primer concentrations, we achieved sufficient read depths to accurately determine methylation levels, even for longer amplicons with partial sequencing strand coverage. This modified assay was used to develop an age estimation model in blood (n = 98) with a mean absolute error (MAE) of 3.22 years and root mean squared error (RMSE) of 3.77 years in the test set (n = 30). Overall, this study demonstrated that by adjusting primer concentrations, equal age estimation performances can be achieved with the added benefit of drastically reduced costs and turn-around-time by using a 2 × 150 bp sequencing strategy. Additionally, this study was the first to independently validate the VISAGE enhanced tool assay on a different sequencing platform, exploring its potential for broader applications and partially answering the need for more uniformity.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
06:40Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
Related Concept Videos
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
DNA Microarrays
Sanger Sequencing
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
UV–Vis Spectrometers
Imaging Biological Samples with Optical Microscopy
In optical microscopy, the specimen to be viewed is placed on a glass slide and clipped on the stage...